Stockreport
G1 Therapeutics to Present at Investor Conferences in March 2018
Last g1 therapeutics earnings: 11/7 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: g1therapeutics.com/pages/investors/investors.htm
PDF
RESEARCH TRIANGLE PARK, N.C., March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the following upcoming investor conferences in March: Cowen and Company 38th Annual Healthcare Conference: Monday, March 12 at 11:20 a.m. ET at the Marriott Copley Place in Boston, MA.Needham & Company 17th Annual Healthcare Conference: Tuesday, March 27 at 8:30 a.m. ET at the Westin Grand Central Hotel in New York, NY. To access the live webcasts of the presentations, please visit the Events & Presentations page within the Investors section of the G1 website. Replays of the webcast will be archived on the same page for 30 days following the event. About G1 TherapeuticsG1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clin
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GTHX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GTHX alerts
GTHX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 THERAPEUTICS news events
Weekly update
A roundup of the hottest topics
GTHX
NEWS
NEWS
- G1 Therapeutics (GTHX) CEO Mark Velleca on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- G1 Therapeutics (GTHX) CEO Mark Velleca on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- G1 Therapeutics Inc (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Cowen Inc.[MarketBeat]
- G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)[GlobeNewswire]
- G1 Therapeutics Inc (NASDAQ: GTHX) had its price target lowered by analysts at Needham & Company LLC from $76.00 to $74.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
GTHX
SEC Filings
SEC Filings
- 11/7/18 - Form 4
- 11/7/18 - Form 4
- 11/7/18 - Form 4
- GTHX's page on the SEC website
- More